SpectRx Cervical Cancer Test Trial Begins In June; Panel Review Anticipated
This article was originally published in The Gray Sheet
Executive Summary
SpectRx expects that data from a pivotal study of its non-invasive cervical cancer detection system will undergo FDA Obstetrics & Gynecology Devices Panel scrutiny after a PMA is submitted